We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

61 hedge funds and large institutions have $175M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $174M → $175M (+$1.11M)

12% less funds holding

Funds holding: 69 → 61 (-8)

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

73% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 15

75% less funds holding in top 10

Funds holding in top 10: 4 → 1 (-3)

Holders
61
Holders Change
-8
Holders Change %
-11.59%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
5
Increased
4
Reduced
15
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PIM
Platinum Investment Management
Australia
+$9.6M
2
ACA
Arena Capital Advisors
California
+$5.29M
3
EC
EcoR1 Capital
California
+$2.2M
4
OPU
Omni Partners US
California
+$2M
5
WP
Woodline Partners
California
+$309K

Top Sellers

Rank Fund Capital Flow
1
MAMNY
Marathon Asset Management (New York)
New York
-$5.79M
2
GCL
Glazer Capital LLC
New York
-$1.92M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.66M
4
SRCM
Sage Rock Capital Management
New York
-$1.59M
5
C
Chescapmanager
Maryland
-$1.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Altium Capital Management
New York
$1.99M – – –
BCM
27
BlueCrest Capital Management
Jersey
$1.49M – – –
Marshall Wace
28
Marshall Wace
United Kingdom
$1.27M +$71.5K +7,202 +6%
CCM
29
Context Capital Management
California
$1.21M -$31.8K -3,200 -3%
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
$1.19M – – –
ACM
31
Altai Capital Management
California
$995K – – –
LOAMU
32
Lombard Odier Asset Management (USA)
New York
$995K – – –
PMAM
33
Picton Mahoney Asset Management
Ontario, Canada
$995K – – –
CH
34
CVI Holdings
Delaware
$992K -$2.98K -300 -0.3%
LC
35
Littlejohn & Co
Connecticut
$726K -$49.7K -5,000 -6%
HF
36
HRT Financial
New York
$701K – – –
Nomura Holdings
37
Nomura Holdings
Japan
$509K – – –
DKCM
38
Davidson Kempner Capital Management
New York
$498K – – –
PSAMP
39
P. Schoenfeld Asset Management (PSAM)
New York
$498K – – –
MF
40
Magnetar Financial
Illinois
$487K -$11.2K -1,127 -2%
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$470K – – –
TD Asset Management
42
TD Asset Management
Ontario, Canada
$442K – – –
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$440K – – –
AA
44
AQR Arbitrage
Connecticut
$387K -$110K -11,100 -22%
SSA
45
Schonfeld Strategic Advisors
New York
$271K +$270K +27,209 New
DAM
46
Deltec Asset Management
New York
$249K – – –
BI
47
Bulldog Investors
New Jersey
$199K – – –
Walleye Trading
48
Walleye Trading
New York
$197K -$4.37K -440 -2%
WRBC
49
W.R. Berkley Corp
Connecticut
$196K – – –
E
50
Ergoteles
New York
$186K – – –
1
2
3

PRDS Hedge Fund Activity: Q3 2021 in Review

61 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q3 2021, worth a combined $175M — up 0.64% from $174M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of PRDS and 5 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 4 added.

The largest buyer was Platinum Investment Management, opening a new position worth an estimated $9.6M. The largest seller was Marathon Asset Management (New York), exiting entirely with an estimated $5.79M sold.

  • 61 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q3 2021, down from 69 in Q2 2021.
  • Funds reported $175M of Pardes Biosciences, Inc. Common Stock stock for Q3 2021, up 0.64% quarter-over-quarter.
  • 5 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q3 2021 and 13 closed out, a net change of -8 holders.
  • The largest Pardes Biosciences, Inc. Common Stock buyer in Q3 2021 was Platinum Investment Management, an estimated $9.6M added.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q3 2021 was Marathon Asset Management (New York), an estimated $5.79M sold.

Based on aggregated 13F filings for Q3 2021.